Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dimerix Limited (AU:DXB)
ASX:DXB
Holding AU:DXB?
Track your performance easily
DXB Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.06 - AU$0.67
Previous CloseAU$0.38
Volume2.10M
Average Volume (3M)3.44M
Market Cap
AU$211.67M
Enterprise ValueAU$202.12M
Total Cash (Recent Filing)AU$9.63M
Total Debt (Recent Filing)AU$73.10K
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
Mar 03, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares OutstandingN/A
10 Day Avg. Volume3,222,466
30 Day Avg. Volume3,437,179
Standard Deviation0.34
R-Squared0.00497
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.33Price Target Upside250.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Dimerix Limited News
PremiumCompany Announcements
Dimerix Advances FSGS Trial with Strategic Partnerships
PremiumCompany Announcements
Dimerix Limited Broadens Market Presence with New Securities
PremiumCompany Announcements
Dimerix Launches Paediatric Trial Site for Kidney Disease
PremiumCompany Announcements
Dimerix Limited Expands Market Presence
PremiumCompany Announcements
Dimerix Advances DMX-200 in Kidney Disease Trial
PremiumCompany Announcements
Dimerix Limited Announces Upcoming AGM
PremiumCompany Announcements
Dimerix Embraces Corporate Governance Excellence
PremiumCompany Announcements
Dimerix Limited Unveils Annual Financial ReportOptions Prices
Currently, No data available
---
Ownership Overview
6.98% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
93.02% Public Companies and
Individual Investors
DXB FAQ
What was Dimerix Limited’s price range in the past 12 months?
Dimerix Limited lowest share price was AU$0.06 and its highest was AU$0.67 in the past 12 months.
What is Dimerix Limited’s market cap?
Currently, no data Available
When is Dimerix Limited’s upcoming earnings report date?
Dimerix Limited’s upcoming earnings report date is Mar 03, 2025 which is in 164 days.
How were Dimerix Limited’s earnings last quarter?
Dimerix Limited released its earnings results on Aug 28, 2024. The company reported -AU$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.021.
Is Dimerix Limited overvalued?
According to Wall Street analysts Dimerix Limited’s price is currently Undervalued.
Does Dimerix Limited pay dividends?
Dimerix Limited does not currently pay dividends.
What is Dimerix Limited’s EPS estimate?
Dimerix Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dimerix Limited have?
Dimerix Limited has 557,031,300 shares outstanding.
What happened to Dimerix Limited’s price movement after its last earnings report?
Dimerix Limited reported an EPS of -AU$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.818%.
Which hedge fund is a major shareholder of Dimerix Limited?
Currently, no hedge funds are holding shares in AU:DXB
---
Dimerix Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.33 (250.00% Upside)
AU$1.33 (250.00% Upside)
Blogger Sentiment
Bullish
AU:DXB Sentiment 97%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
442.85%
12-Months-Change
Fundamentals
Return on Equity
-141.42%
Trailing 12-Months
Asset Growth
80.65%
Trailing 12-Months
Company Description
Dimerix Limited
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
---
DXB Stock 12 Month Forecast
Average Price Target
AU$1.33
▲(250.00% Upside)
Technical Analysis
Best Analysts Covering DXB
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-17.10%
reiterated a buy rating 8 days ago
Copying Tanushree Jain's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -17.10% per trade.
---